Cowen and Company Initiates Coverage on Fate Therapeutics (FATE)
Equities research analysts at Cowen and Company assumed coverage on shares of Fate Therapeutics (NASDAQ:FATE) in a research note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.
Fate Therapeutics (NASDAQ:FATE) opened at 6.87 on Monday. The stock has a 50-day moving average of $0. and a 200-day moving average of $0.. The company’s market cap is $131.6 million.
A number of other analysts have also recently weighed in on FATE. Analysts at Wedbush initiated coverage on shares of Fate Therapeutics in a research note to investors on Monday. They set an “outperform” rating on the stock. Analysts at BMO Capital Markets initiated coverage on shares of Fate Therapeutics in a research note to investors on Monday. They set an “outperform” rating on the stock.
Fate Therapeutics, Inc, is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including hematologic malignancies, lysosomal storage disorders and muscular dystrophies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.